Liraglutide, a human GLP-1 analogue, significantly improves beta cell function in subjects with type 2 diabetes

Similar Items

• Liraglutide, a human GLP-1 analogue, reduces bodyweight in subjects with type 2 diabetes, irrespective of body mass index at baseline
  by: Schmitz, O, et al.
  Published: (2008)
• The reduction of body weight with liraglutide, a once-daily human GLP-I analogue for type 2 diabetes, primarily comes from fat tissue and the fat tissue lost is predominantly visceral fat
  by: Jendle, J, et al.
  Published: (2008)
• Liraglutide, a human GLP-1 analogue, lowers HbA(1c) independent of weight loss
  by: Schmidt, W, et al.
  Published: (2009)
• Liraglutide, a once-daily human GLP-1 analogue, in type 2 diabetes provides similar glycaemic control with reduced body weight compared with glimepiride when added to metformin
  by: Hermansen, K, et al.
  Published: (2008)
• The imaging of insulinomas using a radionuclide-labelled molecule of the GLP-1 analogue liraglutide: a new application of liraglutide.
  by: Jing Lv, et al.
  Published: (2014-01-01)